Small Sample Sizes

Few animals or biological replicates → Low power & unstable estimates

No Power Calculation

Sample size chosen arbitrarily → Study may be underpowered

P-values Just Below 0.05

Results clustering around p = 0.04–0.049 → Possible p-hacking or selective analysis

Multiple Outcomes Without Correction

Many biomarkers or endpoints tested → Higher false-positive rate without correction

Pseudoreplication

Cells or slices counted as true biological replicates → True experimental unit ignored (often the animal)

Missing Randomisation Details

“Randomised” without explaining how → Risk of selection bias

No Blinding

esearchers know treatment groups → Observer bias in measurements

Extremely Large Effect Sizes

Dramatic improvements → Often shrink in replication studies

No Replication, Excessively Controlling Experimental Conditions

Only one experiment or cohort → Findings may be unstable
Overstandardisation → Limit scope of findings, limit reproducibility

Suspicious Graphs

Bar plots without raw data points → Distribution and variability hidden

Reliable preclinical science requires randomisation, blinding, adequate power, and transparent reporting.

Avoid costly statistical pitfalls by consulting an experienced biostatistician at the study design stage. We provide biostatistics mentoring for biotech and medtech teams, drawing on 35+ years of experience.

https://lnkd.in/eT6DdMre